PL3166660T3 - Substancje i sposoby do zastosowania w profilaktyce i/lub leczeniu choroby Huntingtona - Google Patents

Substancje i sposoby do zastosowania w profilaktyce i/lub leczeniu choroby Huntingtona

Info

Publication number
PL3166660T3
PL3166660T3 PL15736262T PL15736262T PL3166660T3 PL 3166660 T3 PL3166660 T3 PL 3166660T3 PL 15736262 T PL15736262 T PL 15736262T PL 15736262 T PL15736262 T PL 15736262T PL 3166660 T3 PL3166660 T3 PL 3166660T3
Authority
PL
Poland
Prior art keywords
huntington
disease
prevention
substances
treatment
Prior art date
Application number
PL15736262T
Other languages
English (en)
Inventor
Oskar SMRZKA
Stefan BARTL
Michela PARTH
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of PL3166660T3 publication Critical patent/PL3166660T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • External Artificial Organs (AREA)
PL15736262T 2014-07-10 2015-07-10 Substancje i sposoby do zastosowania w profilaktyce i/lub leczeniu choroby Huntingtona PL3166660T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176609 2014-07-10
EP15736262.5A EP3166660B1 (en) 2014-07-10 2015-07-10 Substances and methods for the use in prevention and/or treatment in huntington's disease
PCT/EP2015/065795 WO2016005547A1 (en) 2014-07-10 2015-07-10 Substances and methods for the use in prevention and/or treatment in huntington's disease

Publications (1)

Publication Number Publication Date
PL3166660T3 true PL3166660T3 (pl) 2018-07-31

Family

ID=51162585

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15736262T PL3166660T3 (pl) 2014-07-10 2015-07-10 Substancje i sposoby do zastosowania w profilaktyce i/lub leczeniu choroby Huntingtona

Country Status (9)

Country Link
US (5) US10053518B2 (pl)
EP (1) EP3166660B1 (pl)
JP (1) JP2017523165A (pl)
CN (1) CN106687475A (pl)
AU (1) AU2015286606A1 (pl)
DK (1) DK3166660T3 (pl)
ES (1) ES2660372T3 (pl)
PL (1) PL3166660T3 (pl)
WO (1) WO2016005547A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201790165A1 (ru) * 2014-07-29 2017-07-31 Нейриммьюн Холдинг Аг Происходящие от человека антитела к гентингтину (htt) и их применение
CN112390884B (zh) * 2019-04-09 2022-07-08 苏州大学 Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用
CN116535510B (zh) * 2023-06-30 2023-11-10 四川省医学科学院·四川省人民医院 一种抗人pla2r的抗体、试剂盒及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375194B2 (en) 2002-01-28 2008-05-20 California Institute Of Technology Antibodies that bind to an epitope on the Huntington's disease protein
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US7786288B2 (en) * 2003-10-23 2010-08-31 Karp Nelson M Immunizing compositions encoding an epitope obtained from the HIV-1 capsid protein cyclophilin A binding site
ES2845146T3 (es) * 2006-10-09 2021-07-26 Neurofluidics Inc Sistema de purificación de líquido cefalorraquídeo
CA2832521C (fr) * 2011-04-12 2019-10-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Peptides therapeutiques et leur utilisation contre la choree de huntington

Also Published As

Publication number Publication date
AU2015286606A1 (en) 2017-01-12
ES2660372T8 (es) 2019-02-12
US20250051480A1 (en) 2025-02-13
DK3166660T3 (en) 2018-02-05
US20180327513A1 (en) 2018-11-15
EP3166660A1 (en) 2017-05-17
JP2017523165A (ja) 2017-08-17
US20210040236A1 (en) 2021-02-11
ES2660372T3 (es) 2018-03-22
EP3166660B1 (en) 2017-12-13
WO2016005547A1 (en) 2016-01-14
US12065509B2 (en) 2024-08-20
US20220073650A1 (en) 2022-03-10
US20170145117A1 (en) 2017-05-25
CN106687475A (zh) 2017-05-17
US10053518B2 (en) 2018-08-21

Similar Documents

Publication Publication Date Title
GB2568809B (en) Use of cannabinoids in the treatment of epilepsy
GB2568471B (en) Use of cannabinoids in the treatment of epilepsy
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
GB201720020D0 (en) Use of cannabinoids in the treatment of epilepsy
EP3139966A4 (en) Methods and compositions for treating huntington's disease
IL251530A0 (en) Use of cannabinoids in the treatment of skeletal muscle atrophy
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
LT3481846T (lt) 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles
IL249020A0 (en) 1,3,4-thiadiazole compounds and their use in cancer treatment
SMT202500469T1 (it) Combinazione farmaceutica comprendente ponesimod e suo utilizzo nel trattamento della sclerosi multipla
PT3903795T (pt) Unidade de tecido neural e utilização de tal unidade para implantação no sistema nervoso de um mamífero
ZA201604611B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
GB2564459B (en) Use of cannabinoids in the treatment of a neurodegenerative disease or disorder
IL252904A0 (en) Methods and factors for treating diseases
LT3373922T (lt) Kompozicijos ir būdai skirti naudoti homocistinurijos gydyme
IL249122A0 (en) History of imidazole- or 4,2,1-triazole and their use
PL3166660T3 (pl) Substancje i sposoby do zastosowania w profilaktyce i/lub leczeniu choroby Huntingtona
EP3162377A4 (en) Use of -asarone in preparing drugs for preventing and treating alzheimer's disease
IL251407B (en) A multivalent compound for the treatment and prevention of brain damage
IL252493A0 (en) Compounds for use in the prevention or treatment of cancer
EP3110453A4 (en) Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions
PT3191112T (pt) Compostos de dipeptidilcetoamida e sua utilização para o tratamento e/ou prevenção da acumulação de gordura
SG11201701618SA (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases